Synapse Open Synapse
Biology

Another Paragon spinout goes public through reverse merger

BioPharma Dive · · 3 min read

One lawyer involved noted how it's yet another example of Paragon and key investor Fairmount — which have helped transform the reputation for reverse mergers — quickly executing on a complicated deal.

Latest from BioPharma Dive